¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"photon interaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon
    ±¤ÀÚ
  • photon absorption
    ±¤ÀÚÈí¼ö
  • single photon emission computed tomography
    ´ÜÀϱ¤ÀÚ¹æÃâÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(¼ú)
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • additive interaction
    »ó°¡ÀÛ¿ë
  • binocular interaction
    µÎ´«»óÈ£ÀÛ¿ë, ¾ç¾È»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • interaction
    »óÈ£ÀÛ¿ë
  • photon
    ±¤ÀÚ, ±¤·®ÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon absorption
    ±¤ÀÚÈí¼ö
  • photon
    ±¤ÀÚ, ±¤·®ÀÚ
  • single photon emission computed tomography
    ´ÜÀϱ¤ÀÚ¹æÃâ´ÜÃþÃÔ¿µ¼ú
  • additive interaction
    »ó°¡ÀÛ¿ë
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • binocular interaction
    ¾ç¾È»óÈ£ÀÛ¿ë, µÎ´«»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯Àü»óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë
  • infant-mother interaction
    ¿µ¾Æ¾ö¸¶»óÈ£ÀÛ¿ë
  • orbit interaction
    ±Ëµµ»óÈ£ÀÛ¿ë
  • primary interaction
    ÀÏÂ÷»óÈ£ÀÛ¿ë
  • radiation interaction
    ¹æ»ç¼±»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon interaction
    ±¤ÀÚ»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon
    ±¤ÀüÀÚ(ÎÃï³í­).
  • photon
    ±¤ÀÚ
  • J-coupling interaction
    J °áÇÕ »óÈ£ÀÛ¿ë
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • additive interaction
    »ó°¡(ßÓÊ¥)ÀÛ¿ë.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
  • genetic interaction
    À¯ÀüÀû »óÈ£ÀÛ¿ë
  • heme heme interaction
    Èû-Èû »óÈ£ÀÛ¿ë(¡­ßÓû»íÂéÄ).
  • heme heme interaction
    Çð-Çð »óÈ£ÀÛ¿ë(¡­ßÓû»íÂéÄ).
  • infant-mother interaction
    ¿µ¾Æ-¸ð »óÈ£ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ).
  • interaction
    »óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon interaction
    ±¤ÀÚ»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon
    ±¤ÀÚ
  • photon
    ±¤ÀüÀÚ(ÎÃï³í­).
  • single photon emission computed tomography (SPECT)
    ´ÜÀϱ¤ÀÚ¹æÃâÀü»êÈ­´ÜÃþÃÔ¿µ
  • single photon emission computed tomography(SPECT)
    ´ÜÀϾçÀÚ¹æÃâÀü»êÈ­ ´ÜÃþÃÔ¿µ¼ú
  • single photon emission tomography(SPECT)
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • additive interaction
    »ó°¡(ßÓÊ¥)ÀÛ¿ë.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
  • binocular interaction
    ¾ç¾È»óÈ£ÀÛ¿ë
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cellular interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optical photon
    ±¤ÀÚ(ÎÃí­)
  • photon
    ±¤ÀÚ(ÎÃí­)
  • complementary interaction
    »óº¸¼º »óÈ£ÀÛ¿ë(ßÓÜÍàõßÓû»íÂéÄ)
  • crossed hydrophobic interaction immunoelectrophoresis ±³Â÷ ¼Ò¼ö¼º»óÈ£ÀÛ¿ë ¸é¿ªÀü±â¿µµ¿(Îßó©áÂâ©àõßÓû»íÂéÄØóæ¹ï³Ñ¨ç¶
    ÔÑ)
  • dipole-dipole interaction
    ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë(äªÐ¿í­äªÐ¿í­ßÓû»íÂéÄ)
  • dipole-induced dipole interaction
    ½Ö±ØÀÚÀ¯µµ ½Ö±ØÀÚ »óÈ£ÀÛ¿ë(äªÐ¿í­ë¯ÓôäªÐ¿í­ßÓû»íÂéÄ)
  • hydrophobic interaction
    ¼Ò¼ö »óÈ£ÀÛ¿ë(áÂâ©ßÓû»íÂéÄ)
  • hydrophobic interaction chromatography
    ¼Ò¼ö »óÈ£ÀÛ¿ë(áÂâ©ßÓû»íÂéÄ) Å©·Î¸¶Åä±×·¡ÇÇ
  • ion-dipole interaction
    ÀÌ¿Â-½Ö±ØÀÚ(äªÐ¿í­) »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
  • ion induced dipole interaction
    "ÀÌ¿ÂÀ¯µµ(ë¯Óô) ½Ö±ØÀÚ(äªÐ¿í­), »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)"
  • ion-ion interaction
    ÀÌ¿Â-À̿ »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
  • long-range interaction
    ¿ø°Å¸® »óÈ£ÀÛ¿ë(êÀËå×îßÓû»íÂéÄ)
  • lyophobic interaction
    ¼Ò¾×»óÈ£ÀÛ¿ë(áÃäûßÓû»íÂéÄ)
  • nonbonding interaction
    ºñ°áÇÕ»óÈ£¹ÝÀÀ(ު̿ùêßÓû»Úãëë)
  • noncovalent interaction
    ºñ°øÀ¯ »óÈ£ÀÛ¿ë(ÞªÍëêóßÓû»íÂéÄ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon
    ±¤ÀüÀÚ
  • dipolar interaction
    ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • dipole dipole interaction
    ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£ÀÛ¿ë
  • intermolecular dipole dipole interaction
    ºÐÀÚ°£½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • intramolecular dipole dipole interaction
    ºÐÀÚ³»½Ö±ØÀÚ°£»óÈ£ÀÛ¿ë
  • J-coupling interaction
    J°áÇÕ»óÈ£ÀÛ¿ë
  • proton electron dipole dipole interaction
    ¾çÀÚÀüÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ¾çÀÚ½Ö±ØÀÚ½Ö±ØÀÚ»óÈ£¹ÝÀÀ
  • tissue interaction
    Á¶Á÷°£ÀÇ »óÈ£ÀÛ¿ë
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ISSI interview schedule for social interaction; Israeli Study of Surgical Infections
LALI lymphocyte antibody-lymphocytolytic interaction
MDIA multidimensional interaction analysis
MLI mesiolinguoincisal; mixed lymphocyte interaction
MLTI mixed lymphocyte target interaction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BI Binaural Interaction
BIA Biomolecular Interaction Analysis
BIA Biospecific Interaction Analysis
HCI Human Computer Interaction
HIC Hydrophobic Interaction Chromatography
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • additive interaction
    »ó°¡ ÀÛ¿ë
  • heme heme interaction
    Èû-Èû »óÈ£ÀÛ¿ë
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ ÀÛ¿ë
    µÎ °³ ¶Ç´Â ±× ÀÌ»óÀÌ ¼­·Î ¼­·Î ÀÛ¿ëÇÏ´Â ¼ºÁú, »óųª °úÁ¤.
  • nonthermal interaction
    ºñ¿­ »óÈ£ÀÛ¿ë
  • photochemical interaction
    ±¤È­ÇÐ ¹ÝÀÀ
  • photothermal interaction
    ±¤¿­ ¹ÝÀÀ
  • proton proton dipole dipole interaction
    ¾çÀÚ ¾çÀÚ ½Ö±ØÀÚ ½Ö±ØÀÚ »óÈ£ ¹ÝÀÀ
  • triple interaction
    »ïÁß »óÈ£ ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
absorptiometry, photon A noninvasive method for quantitating bone mineral content. It is used especially in the diagnosis of osteoporosis and also in measuring bone mineralization in infants.
(12 Dec 1998)
photon <physics> A quantum unit of light energy.
(09 Oct 1997)
photon density The number of counted events recorded in scintigraphy per square centimeter or per square inch of imaged area.
Synonym: count density.
(05 Mar 2000)
single photon emission computed tomography <radiology> Tomographic imaging of metabolic and physiological functions in tissues, the image being formed by computer synthesis of photons of a single energy emitted by radionuclides administered in suitable form to the patient.
The method uses radionuclides which emit a single photon of a given energy. The camera is then rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer then reconstructs the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the target area scanned.
The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as the size and volume of the organ.
The disadvantage is that, unlike positron emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of available photons and hence degrades the image.
Acronym: SPECT
(20 Jun 2000)
apolar interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
hydrophobic interaction <chemistry> The attractive force between molecules due to the close positioning of non-hydrophilic portions of the two molecules.
(09 Oct 1997)
specimen interaction <microscopy> Reactions that occur inside the specimen when being struck with a beam of energetic electrons or ions.
(05 Aug 1998)
specimen interaction volume <microscopy> The volume inside the specimen in which all specimen interactions occur during electron beam irradiation.
(05 Aug 1998)
DNA-protein interaction <molecular biology> Any complex that forms between a protein molecule and DNA.
Examples are nucleosomes (structures formed for the purpose of DNA storage) and any gene regulatory protein (a protein which regulates transcription by binding to a regulatory region on the DNA).
(09 Oct 1997)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
drug interaction <pharmacology> A chemical or physiologic reaction that can occur when two different medications are taken together and the interaction may affect the metabolism, effectiveness or toxicity of the other.
(18 Jul 2002)
interaction The quality, state or process of (two or more things) acting on each other.
(18 Nov 1997)
interaction process analysis In psychology, analysis of small group behaviour in terms of 12 specific categories, e.g., solidarity, tension release, agreement.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • photon
    ±¤ÀÚ
  • photon engine
    ±¤ÀÚ ·ÎÄÏ
  • interaction
    »óÈ£ÀÛ¿ë
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • interaction
    »óÈ£ÀÛ¿ë;»óÈ£ÀÇ ¿µÇâ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á